Lyra Therapeutics Inc
(NAS:LYRA)
$
0.2952
-0.0149 (-4.8%)
Market Cap: 18.00 Mil
Enterprise Value: -31.26 Mil
PE Ratio: 0
PB Ratio: 0.23
GF Score: 29/100 - Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 13, 2023
- Lyra Therapeutics Inc to discuss the topline results of the BEACON study Call TranscriptSep 12, 2023
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Lyra Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Lyra Therapeutics Inc at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Lyra Therapeutics Inc at Stifel Healthcare Conference TranscriptNov 15, 2022
- Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Lyra Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Lyra Therapeutics Inc at William Blair Growth Stock Conference TranscriptJun 06, 2022
- Lyra Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q3 2021 Lyra Therapeutics Inc Earnings Call TranscriptNov 09, 2021$6.79 (-3.69%)Earnings
- Q2 2021 Lyra Therapeutics Inc Earnings Call TranscriptAug 09, 2021$6.69 (-4.02%)Earnings
- Lyra Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Lyra Therapeutics Inc Earnings Call TranscriptMar 09, 2021$14.6 (+2.17%)Earnings
- Lyra Therapeutics Inc in Maria Palasis & Strong Leadership in HealthTech TranscriptOct 08, 2020
- Q2 2020 Lyra Therapeutics Inc Earnings Call TranscriptAug 05, 2020$13.96 (+1.68%)Earnings
Lyra Therapeutics Inc at Jefferies London Healthcare Conference Transcript
Nov 17, 2022 / 04:25PM GMT
Release Date Price:
$3.9
(+1.04%)
Chris Howerton
Jefferies LLC - Analyst
My name is Chris Howerton, part of the Jefferies biotechnology research team. I am thrilled to be hosting a fireside chat with Lyra Therapeutics, and on behalf of the company, we have the CEO, Dr. Maria Palasis. So thank you so much for joining us, Maria.
Maria Palasis
Lyra Therapeutics, Inc. - CEO, President
Hi, Chris. It's good to be here in London with you.
Chris Howerton
Jefferies LLC - Analyst
Absolutely. I think this is the first time I've been back in two years. So it's nice to see you in person.
Maria Palasis
Lyra Therapeutics, Inc. - CEO, President
Yeah, yeah.
Questions & Answers
Chris Howerton;Maria Palasis
Jefferies LLC - Analyst;Lyra Therapeutics,
All right. So I guess maybe for those that are not totally oriented to the Lyra story, what could you tell us or how would you describe the lead indication of chronic rhinosinusitis?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)